CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B (Progress in Molecular Biology and Translational Science)

CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR –Cas systems for metabolic disorders, Recent progress in CRISPR –Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR –Cas systems for cataract and blindness, Advances in CRISPR –Cas systems for muscular dystrophy, Recent development in CRISPR –Cas systems for cardiac disease, Current approaches in CRISPR –Cas systems for diabetes, and much more. Additional sections cover Advances in CRISPR –Cas systems for liver disease, Advances in CRISPR –Cas systems for lung disease, Advances in CRISPR –Cas systems for kidney diseases, Current progress in CRISPR –Cas systems for rare disease, Advances in CRISPR –Cas systems for heredity disease, Recent progress in CRISPR –Cas systems for neurological disorders, and CRISPR challenges in clinical developments.